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Abstract
BACKGROUND—Uncontrolled bleeding is an important cause of increased transfusion in burn
victims; however, description of blood utilization patterns in the burn population is lacking.
STUDY DESIGN AND METHODS—We conducted a single-institution, retrospective cohort
study to measure blood utilization in 89 consecutive burn patients with 15–65% total body surface
area (TBSA) burn within 60 days of injury. We also evaluated the relationship of blood product
utilization with clinical variables including anticoagulant usage and mortality.
RESULTS—We determined that: (a) the predictors for increased packed red blood cells (PRBC)
and plasma transfusions were high TBSA burn and the use of argatroban anticoagulation (for
suspected heparin-induced thrombocytopenia); (b) TBSA burn and patient age were independent
predictors of mortality, but not PRBC or plasma transfusion; and (c) the incidence of symptomatic
venous thromboembolic events is not uncommon (11.2%), although heparin-induced
thrombocytopenia is rare (1.1%).
CONCLUSION—Despite concerns about adverse correlation between increased number of
transfusions and mortality in other clinical settings, we did not find this association in our study.
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However, we demonstrated that the type and intensity of anticoagulation carries substantial risk
for increased PRBC as well as plasma usage.
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INTRODUCTION
Severe burn injuries are characterized by activation of inflammation and coagulation leading
to coagulation system dysfunction, multi-organ failure, and mortality.1 Following burn
injury, patients experience acute anemia associated with the surgical management of
wounds, iatrogenic blood loss, and anemia of critical illness.2 A variety of therapeutic
strategies are used in clinical practice to control peri-operative bleeding including the use of
local manual pressure, electrocautery, topical soaked epinephrine pads, tumescence,
thrombin and fibrin sealants, tourniquets, and the application of topical hemostatic
dressings.2–4 To date, there is limited literature describing the magnitude of blood utilization
in the burn population. 2,4–9
Given recent heightened concerns that blood transfusion in several clinical settings may be
associated with increased morbidity and mortality,9–18 we measured the number of packed
red blood cells (PRBC) and plasma transfusions administered within 60 days of burn injury
in our institution, and evaluated these data in relation to clinical variables including burn
severity and mortality. We hypothesized that blood utilization might be related to
anticoagulant usage for the prophylaxis or treatment of venous thromboembolic events
(VTE) in this high-risk population. Therefore, we recorded the incidence of VTE as well as
the use and complications of anticoagulant therapy. Furthermore, we hypothesized that the
amount of blood transfusion in 60 days is a marker of burn severity and has independent
adverse effect on survival.
PATIENTS AND METHODS
Study design and objectives
At a single large volume adult and pediatric American Burn Association (ABA)-verified
Burn Center (The Jaycee Burn Center at the University of North Carolina at Chapel Hill),
we conducted a retrospective cohort study and evaluated blood utilization in burn patients
admitted to the Center between January 1, 2008 and December 31, 2009. Recognizing the
heterogeneity of burn severity, we measured the number of PRBC and plasma transfusions
in different total body surface area (TBSA) burn categories to compare their actual blood
utilization. Patients were grouped arbitrarily according to burn severity as 15–30, 31–50,
51–65, and 66–100% total body surface (TBSA) burn.
The primary study objective was to estimate the total number of blood transfusions
administered and to determine its association with TBSA burn, patient age, gender, presence
of co-existing inhalation injury, mechanism of burn injury, type and intensity of
anticoagulant used, presence of VTE, and overall mortality. The diagnosis of co-existing
inhalation injury on admission was suggested by clinical findings of singed nostril hairs and
carbonaceous sputum and confirmed by fiberoptic bronchoscopy. The secondary study
objective was to determine the 60-day incidence of symptomatic VTE including limb deep
vein thrombosis (DVT) and pulmonary embolism (PE) as well as heparin-induced
thrombocytopenia (HIT). The diagnosis of DVT was made by duplex ultrasound, while PE
was diagnosed by chest CT angiography. However, in cases wherein patients’ renal
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dysfunction precluded getting a diagnostic CT angiography, those patients were treated on
the basis of clinical suspicion of PE alone. Both upper and lower extremity DVTs were
included. HIT was defined as a positive heparin-platelet factor 4 antibody test and confirmed
by heparin-dependent platelet aggregation test in the context of suspicious clinical criteria
such as unexplained acute thrombocytopenia, a platelet count that had fallen 50% or more
from baseline, or development of thrombosis associated with new onset
thrombocytopenia.19 Investigation for DVT, PE, and HIT was conducted only if clinically
suspected.
Eligibility criteria
Subjects included adult patients (≥ 18 years old) with 15–100% TBSA burn. All
mechanisms of burn injury were included except electrical injury. Patients with and without
co-existing inhalation injury were included, while patients with associated traumatic injuries
who required medical attention, or patients on therapeutic anticoagulation (heparin or
warfarin) before injury, or with known bleeding disorders were excluded. Burns exceeding
15% TBSA were selected as the lower limit of burn size because burns of this magnitude are
often associated with increased activation of inflammatory and coagulation mediators that
may contribute to adverse clinical outcomes.1 This study was conducted after approval of
the Institutional Review Board of the University of North Carolina.
Patients
Patient demographics such as age, gender, medical history, and mechanism/ extent/ timing
of burn injury were obtained from electronic medical records. The total number of
transfusions of individual blood components— PRBC, plasma, platelets, and
cryoprecipitate– was obtained from the records. Information regarding survival status and
development of VTE within 60 days after injury, as well as types and doses of
anticoagulation used during the 60-day hospitalization period were noted.
As part of routine burn care in our institution, heparin thromboprophylaxis was initiated at
the time of admission and was continued throughout the study period, unless there was an
absolute contraindication. In patients in whom there was a high clinical suspicion for PE due
to acute onset of unexplained hypoxemia in association with severe burn and co-existing
inhalation injury, empiric treatment with therapeutic anticoagulation using heparin was used
until VTE was ruled out, while patients who developed acute thrombocytopenia suspicious
for HIT within the first 2 weeks of hospitalization were treated with a parenteral direct
thrombin inhibitor (i.e. argatroban) until HIT was ruled out. Subsequently these patients
either stayed on therapeutic anticoagulation if VTE was confirmed or were switched to
prophylactic doses of anticoagulation when the suspicion was resolved. Therapeutic
anticoagulation with heparin was not transitioned to warfarin until patients were
hemodynamically stable and preparing for hospital discharge. Thromboprophylaxis was not
routinely held when patients were taken to the operating room for excision and/or grafting
procedures, but therapeutic anticoagulation with intravenous unfractionated heparin was
held for 6–8 hours prior to surgery and gradually resumed once post-operative hemostasis
was established. Ambulation was encouraged throughout the hospital stay, starting from the
day of admission until the first operative procedure, with prompt resumption once post-
operative dressings were taken down. Typically, our transfusion threshold for PRBC is < 7g/
dL in hemodynamically stable patients; however, patients with significant cardiac history
and/or bleeding with or without hemodynamic instability are transfused with PRBCs to keep
their hemoglobin closer to 10 g/dL. Occasionally, patients with larger burns and/or co-
existing cardiac disease are pre-emptively transfused with PRBC to raise their hemoglobin
to 9–10 g/dL before surgery, in anticipation of significant intra-operative bleeding. We try to
minimize intra-operative bleeding by using electrocautery, topical soaked epinephrine pads,
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tumescence, thrombin and fibrin sealants, and the application of topical hemostatic
dressings. Our threshold for plasma transfusion is generally the presence of active bleeding
from wounds and coagulation laboratory abnormalities such as an international normalized
ratio (INR) ≥ 1.5 and prolonged activated partial thromboplastin time (aPTT).
Statistical analysis
We used Kruskal-Wallis tests and chi-square tests, when appropriate, to determine the
association between the number of blood transfusions, 60-day survival status, and patent’s
characteristics, which include TBSA burn, age, gender, mechanism of burn injury, presence
of co-existing inhalation injury, type of anticoagulant used, and VTE. The association was
further adjusted by including multiple covariates in a linear regression model for the
increased number of blood transfusions, and in a logistic regression model for mortality.
Descriptive statistics such as median and range were reported due to skewness of the data. P
values smaller than 0.05 were considered statistically significant. Statistical analyses were
implemented using IBM SPSS Statistics 19 (SPSS, Inc., Chicago, IL).
RESULTS
Patient characteristics
A total of 102 patients with 15–100% TBSA burn were identified. Ten of 13 (76.9%)
patients with 66–100% TBSA burn expired within 48 hours of admission while receiving
comfort care measures. No transfusions were administered to those patients. To eliminate a
possible confounding effect of transfusion on mortality in this 66–100% TBSA group, we
excluded this group of patients from the analysis. Thus, a total of 89 patients with 15–65%
TBSA burn were studied.
The study cohort consisted of 61 males and 28 females. The median age of the cohort was
48.3 years (range: 18.2–90.5 years), while the median TBSA was 22% (range: 15–65%
TBSA). The majority (82.0%) of patients were younger than 65 years old. Sixty-three
patients (70.8%) had 15–30% TBSA burn, while 26 patients (29.2%) had more severe burns,
with 31–65% TBSA burn. The mechanism of burn injury was categorized as flame-related
injuries and others. Flame-related injuries included thermal (48 cases), conflagration (10),
explosion (11), motor vehicle collision (4), and grease burn (9), while others included scald
(3), steam (1), and chemical (3) burns. The majority of patients experienced flame-related
injuries, which accounted for 82 (92.1%) cases. Co-existing inhalation injury was present in
24 patients (27.0%) (Table 1).
Anticoagulation usage
On admission, 76 patients were started on DVT prophylaxis using subcutaneous
unfractionated heparin 5,000 units three times daily (73 cases), enoxaparin either 40 mg
once daily or 30 mg twice daily (2), or fondaparinux 2.5 mg once daily (1), while 11 patients
received empiric therapeutic anticoagulation with either intravenous unfractionated heparin
monitored by an in-house heparin aPTT nomogram (10 cases) or subcutaneous weight-based
enoxaparin at 1 mg/kg twice daily (1). Two patients did not receive pharmacologic
thromboprophylaxis. Together, the majority of patients (87 of 89, 97.7%) received either
prophylactic or therapeutic doses of anticoagulation on admission. Subsequently during the
hospital course, 5 additional patients received therapeutic anticoagulation with either
intravenous unfractionated heparin or subcutaneous low molecular weight heparin (for a
total of 16 patients on therapeutic heparin) due to a clinical suspicion for or confirmed VTE,
while 11 patients were treated with argatroban because of a clinical suspicion for HIT.
Argatroban therapy was initially administered at 1–2 mcg/kg/minute as continuous
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intravenous infusion and was monitored based on our institution’s argatroban protocol by
following serial aPTT measurements.
Association of patient characteristics to number of PRBC and plasma transfusions
A total of 1,233 units of blood products (953 PRBC, 238 plasma, 40 doses of apheresed
platelets, and 2 pools of cryoprecipitate) were administered within 60 days after injury. Of
the 89 patients, 64 (71.9%) received PRBC and 40 (44.9%) received plasma transfusions.
The median number of PRBC and plasma transfusions over 60 days was 6 units (range: 0–
51 units) and 0 unit (range: 0–29 units), respectively. All patients who received plasma
transfusions had also received PRBC transfusions. The patients who received higher
numbers of PRBCs also received higher numbers of plasma transfusions. The majority of
patients who received PRBC transfusion received more than 10 units of PRBC. Nine
patients received at least 1 dose of platelets while a single patient received two pools of
cryoprecipitate. Due to the low volume of platelet and cryoprecipitate transfusions, no
additional analysis of these two components was performed.
The number of PRBC and plasma transfusions was significantly influenced by TBSA burn,
the presence of co-existing inhalation injury, and the type of anticoagulation used. Patients
with more extensive burns had a higher likelihood of receiving more PRBC and plasma
transfusions. This association between TBSA burn and the number of PRBC and plasma
transfusions follows a linear correlation (R2: 0.45 and 0.33 respectively; p < 0.001 for both).
The median number of units of PRBC was 3, 20, and 35 in patients with 15–30, 31–50, and
51–65% TBSA burn, respectively. The corresponding number of units of plasma was 0, 3,
and 4. In patients with co-existing inhalation injury, the median number of PRBC and
plasma units administered was 19 and 3, respectively. In contrast, 3 PRBC and 0 plasma
units were transfused in patients without inhalation injury. Importantly, patients who
received therapeutic anticoagulation with either heparin or argatroban received as much as
5–8 times more PRBC and 2–4 more units of plasma compared to patients who received
only prophylactic anticoagulation. The effects of female gender, flame-related injuries, and
the presence of VTE on the number of PRBC transfusions were also significantly
substantial. Patients with these characteristics received more PRBC transfusions but they did
not influence the number of plasma transfusions. To adjust for confounding variables, a
linear regression analysis showed that the predictors for increased PRBC as well as plasma
transfusions were high TBSA burn and the use of argatroban for anticoagulation. Patients
who were older, female, had flame-related injuries, used heparin for therapeutic
anticoagulation, and had longer hospital stays received more PRBC transfusions. The
presence of co-existing inhalation injury did not have a significant impact on the number of
PRBC or plasma transfusions (Table 2).
Association of patient characteristics to survival
The 60-day overall mortality rate of the cohort was 14.6% (13 of 89 patients). More men
died than women (8 vs. 6), although the number of men in the study markedly outnumbered
the number of women. Survivors were younger than non-survivors [median age of 43 years
(range: 18–77 years) vs. 73 years (range: 26–90 years)], respectively. All deaths were seen
in flame-related injuries. About a third of patients with co-existing inhalation injury died.
The clinical variables that demonstrated significant associations with mortality were TBSA
burn, age, the presence of co-existing inhalation injury, and number of plasma transfusions
(Table 3). In a multivariate logistic regression analysis, the predictors of mortality were
found to be TBSA burn and age [odds ratio: 1.13 (95% CI: 1.03, 1.25) and 1.14 (95% CI:
1.04, 1.24), respectively, both p < 0.05]. The relationship between mortality and the
numbers of PRBC and plasma transfusions did not reach statistical significance. While the
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number of plasma transfusions showed a trend towards mortality (odds ratio: 1.37; 95% CI:
0.99, 1.88; p: 0.055), the effect of the number of PRBC transfusions surprisingly showed a
trend towards survival rather than mortality (odds ratio: 0.89; 95% CI: 0.76, 1.03; p: 0.13).
There was no observed effect of co-existing inhalation injury on mortality. The mechanism
of burn injury, type of anticoagulant used, and the presence of VTE were not included in the
mortality model because of small numbers of patients (Table 4).
Incidence of VTE
Nine patients had radiographically proven DVT, while two patients— one of whom had
HIT– developed PE. Overall, the incidence of symptomatic VTE was 11.2% (10 of 89),
while the incidence of confirmed HIT was 1.1% (1 of 89). Nine of 16 patients who received
therapeutic anticoagulation with heparin ultimately had a confirmed VTE (a 44% false
positive rate), while 1 of 11 patients treated with argatroban was confirmed to have HIT (a
91% false positive rate). The median time to diagnosis of VTE was 15.5 days (range: 4–35
days). The median age and TBSA of patients who developed VTE were 50.5 years (range:
20–73 years) and 20.5% (range: 15–52%), respectively (Table 5). The median time to
initiation of therapeutic anticoagulation with heparin was 24 hours from the time of injury
(range: 1–6 days), while in patients in whom HIT was suspected, the median time to
initiation of argatroban was the third day of admission (range: 1–4 days). All patients who
developed VTE had previously received thromboprophylaxis with unfractionated heparin
and were alive at 60 days after injury.
DISCUSSION
There is limited literature describing blood utilization in burn victims. In 2006, a multi-
center retrospective study reported the effect of blood transfusion on adverse outcomes after
major burn injury. The outcomes analyzed included number of infections, length of hospital
stay, type of anticoagulant used, and mortality. Of the 666 patients with ≥ 20% TBSA burn,
79% survived but received a mean of 14 units of PRBC during hospitalization. Mortality
was related to TBSA burn, patient age, inhalation injury, number of units of blood
transfused outside the operating room, and the total number of transfusions. The number of
infections per patient increased with each unit of blood transfused. The authors hypothesized
that the immunomodulatory potential of blood transfusion could compromise the suppressed
immune system of burn victims, thereby predisposing patients to infection and increased
mortality.9 The adverse effect of blood transfusion on clinical outcomes has been similarly
reported in other patient populations. In trauma, blood transfusion was demonstrated to be
an independent predictor of mortality, intensive care unit admission, systemic inflammatory
response syndrome, ventilator-associated pneumonia, organ dysfunction, and length of
stay.11–14 Among patients undergoing cardiac surgery, the use of a restrictive peri-operative
transfusion strategy compared with a more liberal strategy resulted in non-inferior rates of
the combined outcome of 30-day all-cause mortality and severe morbidity,20 similar to the
results in critically ill medical patients.15
We have shown that predictors for increased PRBC and plasma transfusions were high
TBSA burn and the use of argatroban for therapeutic anticoagulation. While TBSA burn is a
known predictor of increased transfusion,21 the effect of anticoagulation on the number of
transfusions in burn patients has not been fully described, and it is probably underestimated
in clinical practice. In a previous multi-center study, the 35% of patients who were on
anticoagulation during their hospital stay received more PRBC transfusions than those who
were not on anticoagulation (16.3 ± 1.5 vs. 12.3 ± 1.5 units, p <0.001).9 However, in that
study, patients received different doses of anticoagulation (both prophylactic and therapeutic
intents), thereby precluding a meaningful conclusion of the effect of anticoagulation on
number of PRBC transfusions. Also there was no analysis of the number of plasma
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transfusions. In our study, therapeutic anticoagulation using heparin and argatroban was
associated with increased PRBC transfusions, when compared to prophylactic
anticoagulation. Furthermore, argatroban use was not only associated with increased PRBC
transfusions but also increased plasma transfusions. Although the trauma literature has
provided convincing observational studies regarding the clinical benefits of early and
aggressive plasma administration during resuscitation,22–24 there is limited information in
the burn population to guide optimal plasma utilization. It is possible that patients on
therapeutic anticoagulation received both PRBCs to ameliorate anemia and plasma in an
attempt to reverse bleeding. However, this blood utilization practice lacks evidence and
requires further study.
In a multivariate logistic regression model including established risk factors for mortality
(i.e. TBSA burn, age, and presence of co-existing inhalation injury),21 we were able to
demonstrate that TBSA burn and age are independent predictors of mortality. However, we
did not find the number of PRBC or plasma transfusions or the presence of co-existing
inhalation injury to be significantly associated with mortality, which differs from a previous
report.9 However, the number of plasma transfusions showed a trend towards statistical
significance (odds ratio: 1.37; 95% CI: 0.99, 1.88; p: 0.055) suggesting that increased
plasma utilization may be associated with mortality and that our sample size was too small
to detect this association. While we did not find the association of co-existing inhalation
injury and mortality, studies suggest that the presence of co-existing inhalation injury
increases mortality by 20–60%, and burn patients develop a coagulopathy mediated by
systemic activation of coagulation and fibrinolysis,25 which may contribute to their
increased transfusion needs.
Burn patients are perceived to be at risk for VTE due to immobilization, vascular injury,
systemic hypercoagulability, and the use of central venous lines.26–34 However, the degree
to which this hypothesized risk translates into thrombotic events has not been fully
elucidated. While the reported incidence of asymptomatic (radiographically detected) VTE
in a limited number of studies is 6–23%,35–36 the incidence of symptomatic VTE was
reported to be as low as 0.25–2.9%.27–28,33,37–38 This wide variability in incidence may be
largely due to uncontrolled study designs, undiagnosed subclinical VTEs, different sample
sizes and study duration, and whether routine thromboprophylaxis was utilized or not. One
survey showed that about 76% of burn centers in the United States use routine VTE
prophylaxis, varying from lower limb sequential compression devices to varying doses and
types of heparin products.39 As VTEs are increasingly recognized in the burn population,
the American College of Chest Physicians’ guidelines (8th edition, 2008) previously
recommended thromboprophylaxis in burn patients who have additional risk factors for VTE
including advanced age, morbid obesity, extensive or lower extremity burns or concomitant
trauma, use of femoral venous catheter, and/or prolonged immobility (Recommendation
Grade 1A).40 However, in its recent version (9th edition, 2012), this recommendation is not
included.41
Our observed incidence of symptomatic VTE was 11.2 %, while the single case of HIT in
our cohort equated to a frequency of 1.1%. These results indicate that while symptomatic
VTE is not uncommon, HIT is rare. A critical assessment of immune-mediated HIT suggests
a frequency of 0.2–5.0% in patients exposed to heparin for more than 4 days, with an overall
incidence of 2.6% noted in a meta-analysis.42–44 Burn patients are believed to be at low risk
for HIT. Recent studies of burn patients who received heparin thromboprophylaxis found the
incidence of HIT to be 0–1.6%.26,45–46 In comparison, the frequency of HIT in orthopedic
and cardiac surgery patients was reported to be 4.9% and 1.0%, respectively. 45–46 While
extensive data strongly supports the clinical benefit and cost-effectiveness of routine
thromboprophylaxis in trauma, surgical, and medical populations,41 the adverse association
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between increased number of transfusions and possible overzealous use of therapeutic
anticoagulation in our study raises the question about the risk-benefit ratio of routine
anticoagulation. Because it was sometimes difficult or impossible to obtain satisfactory
diagnostic radiology studies on patients with renal dysfunction who were suspected of
having a PE, a number of patients were initiated on therapeutic anticoagulation with heparin
on the basis of clinical suspicion alone. In fact, only 9 of 16 patients who received
therapeutic anticoagulation with heparin ultimately had a confirmed VTE. In addition,
because guidelines have previously recommended the use of full intensity anticoagulation
with a non-heparin parenteral anticoagulant (such as a direct thrombin inhibitor) when there
is moderate to high clinical suspicion of HIT,40–41 a number of our patients were empirically
treated with argatroban while awaiting the results of definitive laboratory studies. In fact,
consistent with other studies, 26,45 only 1 out of 11 patients treated with argatroban was
ultimately confirmed to have HIT. However, because VTE treatment was sometimes
initiated for hypoxemia, which may be seen as part of the natural history of inhalational
injury, and because argatroban was in some cases initiated for early onset thrombocytopenia
(within 72 hours post burn), which may be due to marrow suppression, wound consumption,
and hemodilution from fluid resuscitation,2,47 we acknowledge that there is a need to
enforce more consistent guidelines on the use of therapeutic anticoagulation. In particular,
these results suggest that the risk and benefit of therapeutic anticoagulation must be
individually assessed especially in patients with large burns requiring multiple operations,
who may be at higher risk for both bleeding and thrombosis.
Our study has several limitations. First, this is a single-center study. The second major
limitation is that our transfusion protocol is not standardized. Other limitations include the
retrospective study design, small sample size, short follow-up, and possibility of selection
and referral biases. In addition, information regarding body location(s) of burn injury,
admission body weights, number of operations, and presence of infections and/or multi-
organ dysfunction were not determined, which may be relevant, since these factors may be
considered additional risk factors for VTE and increased transfusion
requirements.2,4,27–28,33,38–40 In patients with a history of cardiovascular disease, we did not
evaluate for concurrent anti-platelet therapy usage, which has been demonstrated to
predispose to post-operative bleeding and increased blood utilization, albeit in cardiac
surgery patients.48 We were also unable to evaluate the immediate cause of death to
determine if bleeding was contributory. Lastly, we measured the total number of blood
transfusions administered within 60 days in relation to TBSA burn, age, gender, presence of
co-existing inhalation injury, and mortality, but did not provide insight into the time course
of blood transfusion in relation to the number of surgical procedures, pre-transfusion
laboratory test results, and indication(s) for transfusion.
Although our population may not be representative of patients seen in all Burn Centers, we
believe that our results may provide useful estimates of transfusion requirements and
anticoagulation prophylaxis practices in burn patients stratified according to TBSA burn.
The results can be used to improve resource allocation of blood products, establish a
benchmark to guide future transfusion-related studies, and improve clinical practice.
CONCLUSIONS
Blood loss is a serious problem in the management of burn patients. Despite concerns about
adverse correlation between quantity of transfusion and mortality in other clinical settings,
we did not find such an association in our study. Nonetheless, it is clear that TBSA burn and
patient age are major predictors of increased PRBC transfusion. In addition, we also
demonstrated that anticoagulation carries substantial risk of iatrogenic bleeding. We
recognize that this study may not reflect other institutions’ practices including surgical
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technique and local transfusion thresholds that may independently contribute to blood
utilization patterns. However, this study provides some compelling preliminary observations
that indicate the need for further investigation.
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Table 3
Association of patients with 15–65% TBSA burn to survival







Total 89 76 (85.4) 13 (14.6)
#of PRBC transfusion (units) 0.131
0 25 (28.1) 21 (27.6) 4 (30.8)
1–10 27 (30.3) 26 (34.2) 1 (7.7)
> 10 37 (41.6) 29 (38.2) 8 (61.5)
#of plasma transfusion (units) <0.001
0 49 (55.1) 45 (59.2) 4 (30.8)
1–6 31 (34.8) 28 (36.8) 3 (23.1)
>6 9 (10.1) 3 (3.9) 6 (46.2)
Total body surface area burn (%) 0.012
15–30 63 (70.8) 58 (76.3) 5 (38.5)
31–50 19 (21.3) 14 (18.4) 5 (38.5)
51–65 7 (7.9) 4 (5.3) 3 (23.1)
Age (years) <0.001
18–40 36 (40.4) 35 (46.1) 1 (7.7)
41–65 37 (41.6) 34 (44.7) 3 (23.1)
>65 16 (18.0) 7 (9.2) 9 (69.2)
Gender 0.556
Male 61 (68.5) 53 (69.7) 8 (61.5)
Female 28 (31.5) 23 (30.3) 5 (38.5)
Mechanism of injury 0.254
Flame-related 82 (92.1) 69 (90.8) 13 (100)
Others 7 (9.2) 7 (9.2) 0 (0)
Inhalation injury 0.018
Yes 24 (27.0) 17 (22.4) 7 (53.8)
No 65 (73.0) 59 (77.6) 6 (46.2)
Type of anticoagulation 0.058
Prophylactic 60 (67.4) 53 (69.7) 7 (53.8)
Heparin therapeutic 16 (18.0) 15 (19.7) 1 (7.7)
Argatroban 11 (12.4) 7 (9.2) 4 (30.8)
None 2 (2.2) 1 (1.3) 1 (7.7)
Venous thromboembolic events 0.165
Yes 10 (11.2) 10 (13.2) 0 (0)
No 79 (88.8) 66 (86.8) 13 (100)
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Table 4
Adjusted logistic regression model for 60-day mortality
Variables Odds Ratio p value 95% CI
Total body surface area burn 1.13 0.012 1.03, 1.25
Age 1.14 0.004 1.04, 1.24
Gender, female 1.21 0.87 0.11, 12.8
Inhalation injury 6.21 0.24 0.30, 127.1
#of PRBC transfusions 0.89 0.13 0.76, 1.03
# of Plasma transfusions 1.37 0.055 0.99, 1.88
Mechanism of injury, type of anticoagulant, and VTE were not included in the mortality model because of non-significance in the bivariate
analysis.
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